Samsung Biologics Co., Ltd.March 14, 2018

FDA 483 - Samsung Biologics Co., Ltd. - March 14, 2018

View on Dashboard

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Samsung Biologics Co., Ltd.

Record Details

An FDA inspection of Samsung Biologics in Incheon, Republic of Korea, identified significant deficiencies in quality assurance oversight and pest control. The firm lacked adequate risk assessment for drug substance intermediates, improperly stored micro testing media, and inadvertently discarded critical bioburden samples. Additionally, the pest control program was deemed inadequate due to variable alert and action limits.

Company: Samsung Biologics Co., Ltd.
Inspection Date: March 14, 2018
Product Type: Drugs
Office: International Compliance Team
People: Thuy T. Nguyen ( Investigator, Consumer Safety Officer)
Riley Myers (investigator)
Ralph M. Bernstein
Alicia Mozzachio (other)

Open in Dashboard

ID · ce260ba9-5da0-4986-9b6e-3fee4fc334d5